News

An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

The FDA approves T-DXd for HER2+ tumors; SynKIR-310 trials begin, and experts debate FLOT vs. CROSS in GEJ cancer in this week’s recap article.

Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.

Yara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.

The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.

Findings from a 3-year follow-up analysis found that nadofaragene firadenovec demonstrated durable, lasting results for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.

In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.

David L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.

Preoperative low-dose radiation did not deliver response rates comparable with higher doses of radiation among patients undergoing surgical resection for esophageal cancer.

Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

PT217 is a first-in-class treatment targeting DLL3 and CD47 for patients with extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.

Debra Patt, MD, PhD, MBA, discussed the ways oncologists can ensure a bright future for themselves and their patients through embracing technology.

Rivoceranib did not produce a statistically significant improvement in overall survival vs placebo, according to findings from the phase 3 ANGEL trial in gastric or gastroesophageal junction cancer.

AI is making strides with its ability to process large amounts of data quickly using organizational platforms and tools that make information more accessible than ever.

Using neoadjuvant atezolizumab followed by atezolizumab plus chemotherapy before surgery for gastric or gastroesophageal junction tumors appeared to be effective and warrants further study.

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.

In an interview with Targeted Oncology, Kim N. Chi, MD, FRCPC, discussed the MAGNITUDE trial results, including patient-reported outcomes, in patients with BRCA-positive mCRPC.

SH-201 is a new, promising option for certain types of leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia, as well as other cancers.

Revumenib shows promise in treating both adults and children with specific types of leukemia, with similar safety and effectiveness.

There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.

Emerging NK-cell therapies offer faster, safer alternatives to CAR T-cell therapy, improving accessibility and reducing manufacturing challenges. T-DXd shows promise in treating HER2+ tumors, and HPV vaccine offerings during abortion care visits improve vaccination rates.

Though osimertinib is the preferred frontline approach to treatment for those with non-small cell lung cancer with classic EGFR mutations, acquired resistance mechanisms invariably develop.